Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoxia and local tumour control. Part 2.

S Dische1

  • 1Marie Curie Research Wing, Regional Centre for Radiotherapy and Oncology, Mount Vernon Hospital, Northwood, Middlesex, U.K.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|January 1, 1991
PubMed
Summary

Clinical trials targeting tumor hypoxia for radiation therapy have underperformed. This may be because hypoxia-induced radioresistance is often coupled with rapid tumor cell repopulation, necessitating a broader understanding of radiosensitivity factors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

CHART revisited: a conservative approach for advanced head and neck cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2007
Same author

From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.

Clinical oncology (Royal College of Radiologists (Great Britain))·2003
Same author

Translational Research--a new entity?

Acta oncologica (Stockholm, Sweden)·2002
Same author

Late morbidity: the Damocles Sword of radiotherapy?

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2001
Same author

Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis.

British journal of cancer·2001

Area of Science:

  • Radiation oncology
  • Tumor microenvironment research
  • Cancer biology

Background:

  • Hypoxia is a known contributor to radioresistance, limiting the effectiveness of radiation therapy.
  • Previous clinical efforts to leverage hypoxia's role in radiation failure have yielded limited success.
  • The interplay between hypoxia and other radioresistance mechanisms remains incompletely understood.

Purpose of the Study:

  • To investigate why clinical strategies targeting tumor hypoxia have not fully translated into improved radiation therapy outcomes.
  • To explore the potential co-existence of rapid repopulation in hypoxic tumors.
  • To emphasize the need for a comprehensive understanding of radiosensitivity factors.

Main Methods:

  • Review of existing laboratory and clinical data on tumor hypoxia and radioresistance.

Related Experiment Videos

  • Analysis of factors contributing to radiation therapy failure.
  • Identification of potential confounding factors in clinical trial design.

    • Main Results:

    • Hypoxia-induced radioresistance may be masked or counteracted by a tumor's capacity for rapid cell repopulation.
    • Tumors exhibiting hypoxia-driven resistance may also possess accelerated proliferation rates.
    • A singular focus on hypoxia overlooks other critical determinants of radiosensitivity.

    Conclusions:

    • Exploiting hypoxia as a sole target for overcoming radiation failure is insufficient.
    • A holistic approach considering all factors influencing radiosensitivity is crucial for effective therapeutic strategies.
    • Future development of hypoxic cell sensitizers requires a comprehensive understanding of tumor biology and radiosensitivity.